• Higashi, Y., Ikeda, S., Matsumoto, K., Satoh, S., Komatsu, A., Sugiyama, H. and Tamanoi, F. (2022) Tumor Accumulation of PIP-Based KRAS Inhibitor KR12 Evaluated by the Use of a Simple, Versatile Chicken Egg Tumor Model. Cancers 2022, 14, 951. doi: 10.3390/cancers14040951

• Komatsu, A., Matsumoto, K., Yoshimatsu, Y., Sin, Y., Kubota, A., Saito, T., Mizumoto, A., Ohashi, S., Muto, M., Noguchi, R., Kondo, T. and Tamanoi, F. (2021) The CAM Model for CIC-DUX4 Sarcoma and Its Potential Use for Precision Medicine. Cells. 10, 2613. doi: 10.3390/cells10102613.

• Higashi, Y., Matsumoto, K., Saitoh, H., Shiro, A., Ma, Y., Laird, M., Chinnathambi, S., Birault, A., Doan, T.L.H., Yasuda, R., Tajima, T., Kawachi, T. and Tamanoi, F. (2021) Iodine containing porous organosilica nanoparticles trigger tumor spheroids destruction upon monochromatic X-ray irradiation: DNA breaks and K-edge energy X-ray. Sci. Rep. 11, 14192. doi: 10.1038/s41598-021-93429-9.

• Gisbert-Garzarán, M., Lozano, D., Matsumoto, K., Komatsu, A., Manzano, M., Tamanoi, F. and Vallet-Regí, M. (2021) Designing Mesoporous Silica Nanoparticles to Overcome Biological Barriers by Incorporating Targeting and Endosomal Escape. ACS Appl Mater Interfaces 13, 9656-9666. doi: 10.1021/acsami.0c21507.

• Tamanoi, F., Chinnathambi, S., Laird, M., Komatsu, A., Birault, A., Takata, T., Doan, T.L., Mai, N.X.D., Raitano, A., Morrison, K., Suzuki, M. and Matsumoto, K. (2021) Construction of Boronophenylalanine-Loaded Biodegradable Periodic Mesoporous Organosilica Nanoparticles for BNCT Cancer Therapy. Int. J. Mol. Sci. 22, 2251. doi: 10.3390/ijms22052251.

• Chinnathambi, S. and Tamanoi, F. (2020) Recent Development to Explore the Use of Biodegradable Periodic Mesoporous Organosilica (BPMO) Nanomaterials for Cancer Therapy. Pharmaceutics. 12, 890. doi: 10.3390/pharmaceutics12090890.

• Tamanoi, F., Matsumoto, K., Saitoh, H. and Shiro, A. (2020)「単色X 線とナノ粒子を組み合わせた新しいがん治療技術の開発にむけて」, Isotope News〔No.770〕2020年8月号, pp.7-11.

• Tamanoi, F., Matsumoto, K., Doan, T.L.H., Shiro, A. and Saitoh, H. (2020) Studies on the Exposure of Gadolinium Containing Nanoparticles with Monochromatic X-rays Drive Advances in Radiation Therapy. Nanomaterials (Basel). 10, 1341. doi: 10.3390/nano10071341.

• Mai, N.X.D., Birault, A., Matsumoto, K., Ta, H.K.T., Intasa-Ard, S.G., Morrison, K., Thang, P.B., Doan, T.L.H. and Tamanoi, F. (2020) Biodegradable Periodic Mesoporous Organosilica (BPMO) Loaded with Daunorubicin: A Promising Nanoparticle-Based Anticancer Drug. ChemMedChem. 15, 593-599. doi: 10.1002/cmdc.201900595.

Latest Press Release!!

We have reported that PIP-Based KRAS inhibitor KR12 exhibits excellent tumor accumulation properties. We evaluated PIP portion of KR12 for its tumor accumulation capability using the CAM assay, a simple and versatile chicken egg tumor model. As a result, we have shown that the PIP contained in KR12 exhibits remarkable tumor accumulation and localizes near the nucleus. KR12 also inhibit tumor growth in the CAM model. Thus, it is expected that new KRAS inhibitors will be developed and the CAM assay will be useful for evaluation of tumor accumulation.

KRAS阻害剤として開発されたKR12 に含まれたピロールイミダゾールポリアミド(PIP)の強い腫瘍蓄積に関する研究成果を発表しました。

PIPはDNAに結合して遺伝子発現を抑える物質として注目されています。本研究ではKRAS発現阻害剤として開発されたKR12が強い腫瘍蓄積能を持つことを報告しました。また、このPIPは細胞核の周辺部へ局在することが示され、腫瘍の成長を阻害することも示されました。私たちの実験は簡素かつ多用途な鶏卵モデルであるCAMモデルを用いて行われました。このことは、PIPを基盤にした新規KRAS阻害剤の開発の可能性を示唆しています。

[Publication]

Higashi, Y., Ikeda, S., Matsumoto, K., Satoh, S., Komatsu, A., Sugiyama, H. and Tamanoi, F. (2022) Tumor Accumulation of PIP-Based KRAS Inhibitor KR12 Evaluated by the Use of a Simple, Versatile Chicken Egg Tumor Model. Cancers 2022, 14, 951. doi: 10.3390/cancers14040951